Evidence map›Paper›PMID 37936324›Full record

ArticleNeuro-oncology2024

Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalization via macropinocytosis.

Sarah J Derby, Louise Dutton, Karen E Strathdee, Katrina Stevenson, Anna Koessinger, Mark Jackson, Yuling Tian, Wenxi Yu, Kathy Mclay, Josette Misquitta and 20 more

Open access · hybridAbstract read
In one paragraph

Article in Neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Glycosylation Gene Signatures as Prognostic Biomarkers in Glioblastoma.Annals of clinical and translational neurology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Functionally-instructed modifiers of response to ATR inhibition in experimental glioma.Journal of experimental & clinical cancer research : CR · 2024
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 4 institutions in 3 countries.

Sarah J DerbyWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Louise DuttonWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Karen E StrathdeeWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Katrina StevensonWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Anna KoessingerWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Mark JacksonWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Yuling TianWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Wenxi YuWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Kathy MclayWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Josette MisquittaWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Sama AlsharifWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Cassie J ClarkeCRUK Scotland Institute, Glasgow, UK.
Lesley GilmourWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Peter ThomasonCRUK Scotland Institute, Glasgow, UK.
Ewan McGheeCRUK Scotland Institute, Glasgow, UK.
Connor L McGarrity-CottrellDepartment of Oncology and Metabolism, The University of Sheffield Medical School, Sheffield, UK.
Aurelie VanderlindenDepartment of Oncology and Metabolism, The University of Sheffield Medical School, Sheffield, UK.
Spencer J CollisDepartment of Oncology and Metabolism, The University of Sheffield Medical School, Sheffield, UK.
Ola RominyiDepartment of Oncology and Metabolism, The University of Sheffield Medical School, Sheffield, UK.
Leandro LemgruberCellular Analysis Facility, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Gergely SoleckiGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael OlsonDepartment of Chemistry and Biology, Ryeson University, Toronto, Ontario, Canada.
Frank WinklerGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0003-4892-6104
Leo M CarlinWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Dieter Henrik HeilandMILO Laboratory, Department of Neurosurgery, Freiburg, Germany.
Gareth J InmanWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Anthony J ChalmersWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Jim C NormanWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-0098-3014
Ross CarruthersWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
Joanna L BirchWolfson Wohl Translational Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, UK.
University of Glasgow · GBUniversity of Sheffield · GBGerman Cancer Research Center · DEToronto Metropolitan University · CA

Funding

Cancer Research UK 23983Cancer Research UK 29802Cancer Research UK A31287Cancer Research UK C16583/A28803Medical Research Council MR/R009473/1Medical Research Council MR/T04358X/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/P001335/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/T002093/1
6 · The paper itself

Abstract

backgroundGlioblastomas have highly infiltrative growth patterns that contribute to recurrence and poor survival. Despite infiltration being a critical therapeutic target, no clinically useful therapies exist that counter glioblastoma invasion. Here, we report that inhibition of ataxia telangiectasia and Rad 3 related kinase (ATR) reduces invasion of glioblastoma cells through dysregulation of cytoskeletal networks and subsequent integrin trafficking.

methodsGlioblastoma motility and invasion were assessed in vitro and in vivo in response to ATR inhibition (ATRi) and ATR overexpression using time-lapse microscopy, two orthotopic glioblastoma models, and intravital imaging. Disruption to cytoskeleton networks and endocytic processing were investigated via high-throughput, super-resolution and intravital imaging.

resultsHigh ATR expression was associated with significantly poorer survival in clinical datasets while histological, protein expression, and spatial transcriptomics using glioblastoma tumor specimens revealed higher ATR expression at infiltrative margins. Pharmacological inhibition with two different compounds and RNAi targeting of ATR opposed the invasion of glioblastoma, whereas overexpression of ATR drove migration. Subsequent investigation revealed that cytoskeletal dysregulation reduced macropinocytotic internalization of integrins at growth-cone-like structures, resulting in a tumor microtube retraction defect. The biological relevance and translational potential of these findings were confirmed using two orthotopic in vivo models of glioblastoma and intravital imaging.

conclusionsWe demonstrate a novel role for ATR in determining invasion in glioblastoma cells and propose that pharmacological targeting of ATR could have far-reaching clinical benefits beyond radiosensitization.

Indexed as

GlioblastomaAtaxia Telangiectasia Mutated ProteinsCell Line, TumorCytoskeletonHumansIntegrinsNeoplasm InvasivenessAtaxia Telangiectasia Mutated ProteinsATR protein, humanIntegrinsATRDNA damage responseglioblastomahigh-grade gliomainvasionmacropinocytosis

Identifiers

PMID37936324
PMCPMC10995506
OpenAlexW4388486354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.